Iron deficiency is one of the most common nutritional disorders worldwide and a major public health concern in India. It affects people across all age groups, particularly women, children, chronic kidney disease patients, and individuals with poor dietary intake or malabsorption disorders. Untreated iron deficiency can lead to iron deficiency anaemia, causing fatigue, weakness, shortness of breath, reduced immunity, and impaired quality of life.
RUDIX FCM IV, containing Ferric Carboxymaltose Injection, is a modern intravenous iron therapy designed to quickly replenish iron stores in the body. Unlike oral iron supplements, which may take weeks or months to show results and often cause gastrointestinal side effects, ferric carboxymaltose delivers iron directly into the bloodstream. This ensures rapid correction of iron deficiency with improved patient compliance and predictable outcomes.
RUDIX FCM IV is widely used in hospital and clinical settings for patients who require fast, effective, and well-tolerated iron replacement therapy.
Uses of RUDIX FCM IV
RUDIX FCM IV is indicated for the treatment of iron deficiency and iron deficiency anaemia in various clinical conditions, especially when oral iron therapy is ineffective or unsuitable.
Key uses include:
Treatment of iron deficiency anaemia
Iron replacement in patients with chronic kidney disease
Management of iron deficiency in pregnant and postpartum women, as advised by a doctor
Iron supplementation in patients with heavy menstrual bleeding
Treatment of iron deficiency due to malabsorption syndromes
Iron deficiency associated with inflammatory bowel disease
Patients intolerant to or non-responsive to oral iron supplements
Rapid iron repletion before or after surgical procedures
RUDIX FCM IV is particularly beneficial in conditions requiring quick restoration of iron levels.
Benefits of RUDIX FCM IV
RUDIX FCM IV offers multiple advantages over conventional oral and older intravenous iron preparations:
Rapid replenishment of iron stores in a single or few doses
High-dose iron delivery with controlled release
Improves haemoglobin levels effectively
Reduced need for frequent hospital visits
Better patient compliance compared to oral iron
Lower risk of gastrointestinal side effects
Suitable for patients with poor absorption of oral iron
Clinically proven safety and efficacy profile
By correcting iron deficiency efficiently, RUDIX FCM IV helps improve energy levels, physical performance, cognitive function, and overall well-being.
Dosage
The dosage of RUDIX FCM IV depends on the patient’s body weight, haemoglobin level, and total iron deficit. The injection must be administered under the supervision of a qualified healthcare professional.
General dosage guidelines include:
Administered as an intravenous injection or infusion
A single dose may deliver up to 1000 mg of iron, depending on clinical requirement
The injection can be given as a slow IV push or diluted IV infusion
The total dose may be divided into multiple administrations if required
Monitoring of haemoglobin and iron parameters is recommended
RUDIX FCM IV should never be self-administered. Dosage and frequency must be determined by the treating physician.
Side Effects of RUDIX FCM IV
RUDIX FCM IV is generally well tolerated, but like all medications, it may cause side effects in some patients.
Common side effects include:
Headache
Dizziness
Nausea
Injection site pain or swelling
Mild flushing
Less common or rare side effects may include:
Low blood pressure during infusion
Skin rash or itching
Muscle or joint pain
Transient changes in liver enzymes
Hypersensitivity reactions
Severe allergic reactions are rare but require immediate medical attention. Patients are closely monitored during and after administration to ensure safety.
Precautions and Warning
Before using RUDIX FCM IV, the following precautions should be carefully considered:
Should not be used in patients with iron overload disorders
Not recommended in cases of anaemia not caused by iron deficiency
Use cautiously in patients with liver disorders
A test dose is not required, but medical supervision is essential
Emergency equipment should be available during administration
Avoid use during active infection unless advised by a physician
Pregnancy and breastfeeding use should be strictly as per medical advice
Regular monitoring of iron parameters is recommended to avoid iron excess
Inform your doctor about any history of allergies, chronic illnesses, or ongoing medications before receiving RUDIX FCM IV.
Conclusion
RUDIX FCM IV Ferric Carboxymaltose Injection is an advanced and reliable intravenous iron therapy for the effective management of iron deficiency and iron deficiency anaemia. Its ability to deliver high doses of iron safely in a short time makes it an ideal choice for patients who require rapid correction of iron levels or cannot tolerate oral iron therapy.
